Bristol Myers Squibb

Bristol Myers Squibb

Develops and delivers biopharmaceutical medicines

About Bristol Myers Squibb

Simplify's Rating
Why Bristol Myers Squibb is rated
B
Rated B on Competitive Edge
Rated A on Growth Potential
Rated C on Differentiation

Industries

Biotechnology

Healthcare

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1887

Overview

Company Historically Provides H1B Sponsorship

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, particularly in oncology, immunology, and cardiovascular health. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs that are affordable alternatives to their innovative medicines, ensuring they meet high quality and safety standards. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, as well as its commitment to sustainability and corporate responsibility. The company's goal is to improve patient outcomes by providing effective and affordable healthcare solutions while adhering to Environmental, Social, and Governance (ESG) principles.

Simplify Jobs

Simplify's Take

What believers are saying

  • AI-driven drug discovery accelerates BMS's R&D, improving drug development efficiency.
  • BMS's acquisition of 2seventy bio enhances its cancer cell therapy capabilities.
  • Positive Phase 3 trial results for Sotyktu boost BMS's psoriatic arthritis treatment portfolio.

What critics are saying

  • Increased competition in oncology may impact BMS's market share.
  • Layoffs could decrease employee morale, affecting operational efficiency.
  • Integration challenges from acquiring 2seventy bio may pose financial risks.

What makes Bristol Myers Squibb unique

  • BMS focuses on oncology, immunology, and cardiovascular diseases, setting it apart in biopharma.
  • The company integrates AI in early lung cancer diagnosis, enhancing precision care.
  • BMS offers both innovative and generic medicines, increasing healthcare accessibility.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$17914M

Above

Industry Average

Funded Over

2 Rounds

Post IPO Debt funding comparison data is currently unavailable. We're working to provide this information soon!
Post IPO Debt Funding Comparison
Coming Soon

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Company News

European HHHM
Apr 16th, 2025
Optellum Announces Agreement with Bristol Myers Squibb to Leverage AI to Boost Early Lung Cancer Diagnosis

Optellum, a global leader in AI-driven clinical decision support for early lung cancer diagnosis, has entered an agreement with Bristol Myers Squibb (NYSE: BMY), to leverage AI in early diagnosis and precision lung cancer care.

CMMB
Mar 24th, 2025
Our Values, Your Impact

In partnership with Bristol Myers Squibb, Catholic Medical Mission Board Inc. is playing a role in building the infrastructure and workforce to bring quality cancer care to rural Kenya.

PR Newswire
Mar 20th, 2025
Bristol Myers Squibb Appoints Osama Braiwish As General Manager For Saudi Arabia Gulf Countries

RIYADH, Saudi Arabia, March 20, 2025 /PRNewswire/ -- Bristol Myers Squibb, a leading global biopharmaceutical company, has recently appointed Osama Braiwish as its General Manager for Saudi Arabia and Gulf Countries, an affiliate covering Saudi Arabia, United Arab Emirates, Kuwait, Qatar, Oman, Bahrain, and Jordan

Investors Hangout
Mar 20th, 2025
Bristol Myers Squibb Welcomes New Leadership in Gulf Region

Bristol Myers Squibb, a leader in the global biopharmaceutical sector, has appointed Osama Braiwish as its General Manager for the Gulf region, thereby enhancing its capacity to serve medical needs across various specialties.

Business Wire
Mar 12th, 2025
2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb

2seventy bio, Inc. (Nasdaq: TSVT), today announced a definitive merger agreement under which Bristol Myers Squibb (NYSE: BMY) (“BMS”) will acquire all

Recently Posted Jobs

Sign up to get curated job recommendations

Senior Manager – Gxp Computer Systems Validation & IT Process Lead - IT

Indianapolis, IN, USA

Senior Specialist - QC Testing

Phoenix, AZ, USA

Associate Director of CMC - Quality Assurance

Indianapolis, IN, USA

See All Jobs

Bristol Myers Squibb is Hiring for 309 Jobs on Simplify!

Find jobs on Simplify and start your career today

💡
We update Bristol Myers Squibb's jobs every few hours, so check again soon! Browse all jobs →

People Also Viewed

Discover companies similar to Bristol Myers Squibb

Eli Lilly and Company

Eli Lilly and Company

Indianapolis, Indiana

Becton Dickinson

Becton Dickinson

Eysins, Switzerland

Insmed

Insmed

Richmond, Virginia

Senior Specialist - QC Testing

Phoenix, AZ, USA

Associate Director of CMC - Quality Assurance

Indianapolis, IN, USA

See All Jobs

Bristol Myers Squibb is Hiring for 309 Jobs on Simplify!

Find jobs on Simplify and start your career today

💡
We update Bristol Myers Squibb's jobs every few hours, so check again soon! Browse all jobs →

People Also Viewed

Discover companies similar to Bristol Myers Squibb

Eli Lilly and Company

Eli Lilly and Company

Indianapolis, Indiana

Becton Dickinson

Becton Dickinson

Eysins, Switzerland

Insmed

Insmed

Richmond, Virginia